The inhibiting factors most frequently spontaneously reported by the GPs were only very few palliative care patients in their practice during the
course (11x) and not enough time available for the training Selleck NLG-8189 programme (10x). Inhibiting factors reported by the GPTs were that medical elements were lacking in the programme (5x) and Inhibitors,research,lifescience,medical that not all steps in the programme had been addressed (3x). During the 6months duration of the programme the GPTs provided palliative care for an average of two patients (range 0–5). Discussion Main findings We developed the ACA training programme to improve communication between GPs and their palliative care patients, consisting of eight consecutive steps, and based on three key areas of attention in communication: availability of the GP for the patient, current issues that should be raised by the GP, and anticipating various scenarios. The results of this study show that the programme appears to be applicable to practising GPs Inhibitors,research,lifescience,medical who attended a 2-year Palliative Care Peer Group Training Inhibitors,research,lifescience,medical Course and to (inexperienced) GPTs from five vocational training groups. The ACA checklist was appreciated by GPs as useful both in practice and as a learning tool, whereas GPTs mainly appreciated the list for use in practice. A quarter of the GPs
and a third of the Inhibitors,research,lifescience,medical GPTs spontaneously reported the ACA checklist to be a useful guide for communication with palliative care patients. Strengths and limitations of this study Both content and educational approach of the ACA training programme are evidence-based. The content of the ACA training programme is based on the results of recent studies among palliative
care patients, their relatives, GPs, and end-of-life consultants. The educational approach was derived from two systematic Inhibitors,research,lifescience,medical reviews of methods in training programmes for communication in palliative and cancer care. Attendance and appreciation of the training programme were evaluated for each step of the programme. The newly developed training programme was assessed among practising GPs and inexperienced GPTs. The GPs participated Cediranib (AZD2171) in a two-year Palliative Care Peer Group Training Course, and probably had a more than average commitment to palliative care, unlike the GPTs, who participated as part of their vocational training, with no special commitment. This might explain the moderate GPT response rate (67%) and their lower scores for appreciation. The appreciation scores of the two groups can only be compared with caution, because the GPs scored their appreciation on a 10-point scale and the GPTs on a 5-point scale. Non-responding GP(T)s might have had lower attendance rates and lower appreciation scores.